Study guide

2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function

Philippine Medical Technologists Licensure Examination MTLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Clinical Chemistry: Laboratory Operations, Instrumentation, Reagents, Quality Assurance, and Safety

1.1 Specimen Collection, Preanalytical Variables, and Interferences 1.2 Clinical Chemistry Instrumentation, Photometry, and Automation 1.3 Quality Control, Westgard Rules, Calibration, and Laboratory Mathematics 1.4 Reagent Preparation, Laboratory Water, Glassware, Pipettes, and Centrifuges 1.5 Laboratory Safety: Chemical, Fire, Electrical, Biological, and Physical Hazards

2 Chapter 2: Clinical Chemistry: Carbohydrates, Lipids, Proteins, Non-Protein Nitrogen, and Liver Function

2.1 Glucose Homeostasis, Diagnostic Criteria for Diabetes Mellitus, and Glycemic Monitoring 2.2 Lipids, Lipoproteins, Apolipoproteins, and Coronary Heart Disease Risk Assessment 2.3 Serum Proteins, Albumin, Globulins, and Serum Protein Electrophoresis Patterns 2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function 2.5 Liver Function Tests, Bilirubin Metabolism, and Jaundice

3 Chapter 3: Clinical Chemistry: Electrolytes, Blood Gases, Enzymology, Endocrinology, and Toxicology

3.1 Water Balance, Electrolytes, Osmolality, and Anion Gap Calculations 3.2 Blood Gas Analysis, Oxygenation, and Acid-Base Homeostasis 3.3 Clinical Enzymology: Enzyme Kinetics, Cardiac Biomarkers, and Hepatic and Pancreatic Enzymes 3.4 Endocrinology: Hormone Physiology and Endocrine Function Testing 3.5 Therapeutic Drug Monitoring and Clinical Toxicology

4 Chapter 4: Bacteriology: Specimen Management, Media, Staining, and Biosafety

4.1 Specimen Collection, Transport, Processing, and Microscopic Staining 4.2 Culture Media Classification, Quality Control, and Inoculation Techniques 4.3 Sterilization, Disinfection, Decontamination, and Biosafety Containment 4.4 Antimicrobial Susceptibility Testing Methods, Standardization, and Resistance Mechanisms

5 Chapter 5: Diagnostic Bacteriology: Major Pathogenic Bacteria

5.1 Medically Important Gram-Positive Cocci: Staphylococci, Streptococci, and Enterococci 5.2 Medically Important Gram-Negative Bacilli: Enterobacterales and Non-Fermenters 5.3 Fastidious, Microaerophilic, and Anaerobic Bacteria 5.4 Mycobacteria, Spirochetes, Atypical Bacteria, and Public Health Microbiology

6 Chapter 6: Medical Parasitology, Mycology, and Diagnostic Virology

6.1 Stool Examination Techniques and Intestinal Nematodes 6.2 Tissue Nematodes, Filarial Worms, Cestodes, and Trematodes 6.3 Medical Protozoology: Intestinal, Urogenital, and Blood/Tissue Protozoa 6.4 Medical Mycology: Yeasts, Dermatophytes, Dimorphic Fungi, and Opportunistic Molds 6.5 Clinical Virology: Viral Structure, Specimen Handling, and Diagnostic Methods

7 Chapter 7: Hematology: Specimen Collection, Routine Parameters, Instrumentation, and Manual Methods

7.1 Blood Specimen Collection, Anticoagulants, Preanalytical Variables, and Specimen Quality 7.2 Automated Cell Counting Principles, Complete Blood Count Parameters, and Erythrocyte Indices 7.3 Reticulocyte Evaluation, Supravital Staining, and Erythrocyte Sedimentation Rate 7.4 Manual Cell Counts, Manual Hemoglobin Methods, and Hematology Quality Control

8 Chapter 8: Hematology: Blood Cell Morphology, Bone Marrow, and Hematologic Disorders

8.1 Normal Erythropoiesis and Erythrocyte Morphologic Abnormalities 8.2 Anemias: Classification, Iron Deficiency, Megaloblastic, Hemolytic, and Hemoglobinopathies 8.3 Normal Leukopoiesis, Leukocyte Differential, and Non-Malignant White Cell Alterations 8.4 Hematologic Malignancies: Acute and Chronic Leukemias, Myeloproliferative and Lymphoproliferative Disorders 8.5 Peripheral Blood Smear Preparation and Staining, Bone Marrow Examination, and Cytochemistry

9 Chapter 9: Hemostasis: Coagulation and Platelet Function Testing and Hemostatic Disorders

9.1 Mechanisms of Primary and Secondary Hemostasis, Fibrinolysis, and Natural Inhibitors 9.2 Coagulation Laboratory Testing: PT/INR, aPTT, Fibrinogen, Thrombin Time, and Mixing Studies 9.3 Hemostatic and Thrombotic Disorders: Hemophilias, von Willebrand Disease, DIC, and Thrombophilias 9.4 Bleeding Time, Clotting Time, Platelet Function, and Special Hematology Tests

10 Chapter 10: Immunohematology: Blood Group Systems and Antiglobulin Testing

10.1 The ABO Blood Group System, Genetics, Subgroups, and Forward/Reverse Typing Discrepancies 10.2 The Rh Blood Group System, Weak D Testing, and Other Major Blood Group Systems 10.3 Antiglobulin Testing, Elution, Adsorption, and Special Antibody Procedures

11 Chapter 11: Blood Banking: Donor Operations, Component Therapy, and Adverse Reactions

11.1 Donor Selection, Physical Examination, Screening, and Mandatory Infectious Marker Testing 11.2 Blood Component Preparation, Storage, Expiration, and Indications for Transfusion 11.3 Pre-Transfusion Compatibility Testing and Transfusion Reactions 11.4 Hemolytic Disease of the Fetus and Newborn (HDFN) and Rh Immune Globulin

12 Chapter 12: Clinical Serology and Immunology

12.1 Principles of Immunology: Antigens, Antibodies, Complement, and Immune Responses 12.2 Serologic Testing Methodologies: Agglutination, Precipitation, Flocculation, and Labeled Immunoassays 12.3 Infectious Disease Serology: Syphilis, Viral Hepatitis Markers, HIV, Dengue, and Febrile Agglutinins 12.4 Autoimmune Serology, Hypersensitivity, Immunodeficiencies, and Histocompatibility (HLA)

13 Chapter 13: Clinical Microscopy: Urinalysis and Renal Pathology

13.1 Renal Physiology, Urine Formation, and Physical Examination of Urine 13.2 Chemical Examination of Urine: Reagent Strip Principles, Interferences, and Confirmatory Tests 13.3 Microscopic Examination of Urine Sediment: Cells, Casts, Crystals, and Contaminants 13.4 Renal Calculi, Glomerular/Tubular/Interstitial Renal Diseases, and Urinalysis Quality Control

14 Chapter 14: Clinical Microscopy: Body Fluids, Fecal Analysis, and Gastric, Duodenal, and Respiratory Specimens

14.1 Cerebrospinal Fluid Analysis: Collection, Cell Counts, Chemistry, and Microbiology 14.2 Serous Fluids (Pleural, Pericardial, Peritoneal: Transudates vs Exudates) and Synovial Fluid Analysis 14.3 Seminal Fluid and Amniotic Fluid Analysis 14.4 Fecal Analysis: Macroscopic, Microscopic, and Chemical Examination of Stool 14.5 Gastric Fluid, Duodenal Contents, Sputum, and Bronchoalveolar Specimens

15 Chapter 15: Histopathologic Techniques and Cytotechnology

15.1 Tissue Preservation, Fixation, Decalcification, and Processing Steps 15.2 Microtomy, Sectioning Artifacts, Hematoxylin and Eosin Staining, and Special Stains 15.3 Cytotechnology: Specimen Collection, Fixation, Papanicolaou Staining, and the Bethesda System 15.4 Special Procedures: Frozen Sections, Special Embedding, Immunohistochemistry, Electron Microscopy, Autopsy, Museum Techniques, and Laboratory Records

16 Chapter 16: Medical Technology Laws, Related Laws, and Ethics

16.1 Republic Act No. 5527 (The Philippine Medical Technology Act of 1969) and Key Amendments 16.2 Related Philippine Healthcare Laws, Code of Ethics, and Bioethics

2.4 Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function

Key Takeaways Explain This Topic AI

Blood urea nitrogen (BUN) is synthesized in the liver via the urea cycle and reabsorbed passively by renal tubules, whereas creatinine is produced from muscle creatine at a constant daily rate and excreted almost solely by glomerular filtration.

A BUN-to-creatinine ratio > 20 : 1 > 20:1 > 20 : 1 with a normal or mildly elevated creatinine indicates prerenal azotemia caused by hypoperfusion, whereas intrinsic renal damage yields a ratio between 10 : 1 10:1 10 : 1 and 15 : 1 15:1 15 : 1 with proportional elevations in both markers.

The Jaffe reaction forms a red-orange Janovski complex with alkaline picrate at 500-520 nm; kinetic Jaffe timing between 20 and 80 seconds minimizes interference from non-creatinine chromogens including acetoacetate, cephalosporins, and glucose.

Creatinine clearance approximates GFR using the formula C c r = U × V P × 1.73 A C_{cr} = \frac{U \times V}{P} \times \frac{1.73}{A} C cr ​ = P U × V ​ × A 1.73 ​ , while serum Cystatin C serves as a GFR marker that depends far less on muscle mass and diet than creatinine does.

Hyperuricemia results from purine nucleoside catabolism, leading to monosodium urate crystal deposition in joints (gout) or renal tubule precipitation during tumor lysis syndrome; uricase catalyzes the conversion of uric acid to allantoin with a stoichiometric decrease in absorbance at 293 nm.

Last updated: October 2026

Non-Protein Nitrogen Compounds: Urea, Creatinine, Uric Acid, and Renal Function

Non-protein nitrogen (NPN) compounds are the low-molecular-weight catabolic waste products remaining in a protein-free filtrate following chemical precipitation of plasma proteins. Historically quantified collectively to evaluate renal excretory performance, individual NPN compounds—primarily urea , creatinine , and uric acid —are now measured via discrete automated enzymatic and chemical methods. Understanding their metabolic synthesis, renal handling, and analytical interferences is critical for evaluating renal function, assessing glomerular filtration, and classifying azotemia.

1. Non-Protein Nitrogen Fraction Distribution

In normal human plasma, the total NPN concentration ranges from 20 to 35 mg/dL 20\text{ to }35\text{ mg/dL} 20 to 35 mg/dL , distributed across the following compounds:

  • Urea: 45 % to 50 % 45\%\text{ to }50\% 45% to 50% of total NPN (predominant circulating waste product)
  • Free Amino Acids: ≈ 25 % \approx 25\% ≈ 25%
  • Uric Acid: ≈ 10 % \approx 10\% ≈ 10%
  • Creatinine: ≈ 5 % \approx 5\% ≈ 5%
  • Creatine: ≈ 1 − 2 % \approx 1 - 2\% ≈ 1 − 2%
  • Ammonia: ≈ 0.2 % \approx 0.2\% ≈ 0.2%
  • 2. Blood Urea Nitrogen (BUN) and Urea Metabolism
  • Biosynthesis and Renal Elimination

Hepatic Urea Cycle (Krebs-Henseleit Cycle): Amino acid catabolism generates toxic free ammonia ( NH 3 \text{NH}_3 NH 3 ​ ). Hepatocytes neutralize ammonia by synthesizing non-toxic, water-soluble urea via the hepatic urea cycle. Key enzymes include carbamoyl phosphate synthetase I, ornithine transcarbamylase, argininosuccinate synthetase, argininosuccinate lyase, and arginase.

Renal Handling: Urea is freely filtered by the glomeruli. However, 40 % to 70 % 40\%\text{ to }70\% 40% to 70% of filtered urea is passively reabsorbed by the renal tubular epithelium back into the peritubular capillaries. Tubular urea reabsorption is highly flow-dependent: in volume-depleted states (dehydration, hypotension, congestive heart failure), slow tubular flow maximizes urea reabsorption, causing blood urea levels to climb sharply. During high tubular flow (hyperhydration, diuresis), reabsorption drops toward 40 % 40\% 40% .

Stoichiometry, Units, and Interconversion

In the United States and MTLE board conventions, laboratories routinely measure Blood Urea Nitrogen (BUN) , reporting the mass of nitrogen present within urea. The molecular weight of urea [ CO(NH 2 ) 2 ] [\text{CO(NH}_2)_2] [ CO(NH 2 ​ ) 2 ​ ] is 60 g/mol 60\text{ g/mol} 60 g/mol , and it contains two nitrogen atoms ( 28 g/mol 28\text{ g/mol} 28 g/mol N). Therefore: Urea = BUN × 60 28 = BUN × 2.14 \text{Urea} = \text{BUN} \times \frac{60}{28} = \text{BUN} \times 2.14 Urea = BUN × 28 60 ​ = BUN × 2.14 BUN = Urea × 0.467 \text{BUN} = \text{Urea} \times 0.467 BUN = Urea × 0.467

In SI units ( mmol/L \text{mmol/L} mmol/L ), urea concentration is reported directly as the whole molecule: Urea (mmol/L) = BUN (mg/dL) × 0.357 \text{Urea (mmol/L)} = \text{BUN (mg/dL)} \times 0.357 Urea (mmol/L) = BUN (mg/dL) × 0.357

Normal Reference Interval: Adult BUN: 6 to 20 mg/dL 6\text{ to }20\text{ mg/dL} 6 to 20 mg/dL ( 2.1 to 7.1 mmol/L 2.1\text{ to }7.1\text{ mmol/L} 2.1 to 7.1 mmol/L ). Concentrations are higher in elderly individuals and patients on high-protein diets.

Laboratory Analytical Methodologies for Urea

Enzymatic Urease / GLDH Coupled Kinetic Method (Standard Clinical Assay): Urea + 2 H 2 O → Urease 2 NH 4 + + CO 3 2 − \text{Urea} + 2\text{H}_2\text{O} \xrightarrow{\text{Urease}} 2\text{NH}_4^+ + \text{CO}_3^{2-} Urea + 2 H 2 ​ O Urease ​ 2 NH 4 + ​ + CO 3 2 − ​ NH 4 + + α -Ketoglutarate + NADH + H + → Glutamate Dehydrogenase (GLDH) L-Glutamate + NAD + + H 2 O \text{NH}_4^+ + \alpha\text{-Ketoglutarate} + \text{NADH} + \text{H}^+ \xrightarrow{\text{Glutamate Dehydrogenase (GLDH)}} \text{L-Glutamate} + \text{NAD}^+ + \text{H}_2\text{O} NH 4 + ​ + α -Ketoglutarate + NADH + H + Glutamate Dehydrogenase (GLDH) ​ L-Glutamate + NAD + + H 2 ​ O

Principle: Urease hydrolyzes urea to ammonium and carbonate. In the indicator reaction, GLDH catalyzes the reductive amination of α \alpha α -ketoglutarate, oxidizing NADH \text{NADH} NADH to NAD + \text{NAD}^+ NAD + .

Measurement: The initial rate of decrease in absorbance at 340 nm 340\text{ nm} 340 nm is directly proportional to urea concentration.

Conductometric Method: Monitors the rate of increase in specific electrical conductivity as non-ionic urea is hydrolyzed to charged ammonium and carbonate ions.

Berthelot Colorimetric Reaction: Ammonium reacts with sodium hypochlorite and phenol in the presence of nitroprusside catalyst to produce blue indophenol dye ( 560 nm 560\text{ nm} 560 nm ).

Fearon Reaction (Diacetyl Monoxime): Direct chemical reaction of urea with diacetyl monoxime forming a yellow diazine derivative; hazardous acid reagents make it obsolete in routine testing.

Specimen Handling & Interferences: Sodium fluoride gray-top tubes must never be used for urease assays because fluoride ions inactivate urease. Ammonium heparin anticoagulants cause massive false positive elevations from exogenous ammonium.

3. Azotemia Classification and the BUN:Creatinine Ratio

Azotemia denotes an elevated concentration of urea and other nitrogenous wastes in the blood. Uremia describes the clinical syndrome of systemic toxic manifestations (uremic frost, pericarditis, asterixis, encephalopathy, metabolic acidosis) resulting from advanced renal failure.

The BUN:Creatinine ratio (normal: 10 : 1 to 20 : 1 10:1\text{ to }20:1 10 : 1 to 20 : 1 ) is the primary diagnostic algorithm for differentiating azotemia etiologies.

Azotemia Classification BUN:Creatinine Ratio Serum BUN Level Serum Creatinine Level Underlying Pathophysiology Clinical Etiologies

Prerenal Azotemia > 20 : 1 > 20:1 > 20 : 1 (Often 30 : 1 − 40 : 1 30:1 - 40:1 30 : 1 − 40 : 1 ) Markedly Elevated ( ↑ ↑ \uparrow\uparrow ↑↑ ) Normal or Mildly Elevated Renal hypoperfusion; slow tubular transit induces massive passive reabsorption of urea while creatinine is excreted Congestive heart failure, severe dehydration, hypovolemic shock, GI hemorrhage, high-protein catabolism

Renal (Intrinsic) Azotemia 10 : 1 to 15 : 1 10:1\text{ to }15:1 10 : 1 to 15 : 1 (Normal Ratio) Elevated ( ↑ \uparrow ↑ ) Elevated in parallel ( ↑ \uparrow ↑ ) Intrinsic parenchymal nephron damage impairs filtration of both markers; damaged tubules fail to reabsorb urea Acute tubular necrosis (ATN), acute glomerulonephritis, bilateral interstitial nephritis, end-stage CKD

Postrenal Azotemia > 20 : 1 > 20:1 > 20 : 1 initially , returning to 10 : 1 − 15 : 1 10:1 - 15:1 10 : 1 − 15 : 1 Markedly Elevated ( ↑ ↑ \uparrow\uparrow ↑↑ ) Markedly Elevated ( ↑ ↑ \uparrow\uparrow ↑↑ ) Urinary tract obstruction causes retrograde hydrostatic back-pressure, forcing urea back into blood; secondary parenchymal injury Bilateral ureteral calculi, benign prostatic hyperplasia (BPH), prostate or cervical carcinoma, bladder obstruction

Decreased BUN:Cr Ratio < 10 : 1 < 10:1 < 10 : 1 Decreased or Low Normal Normal or Elevated Decreased hepatic urea synthesis; or excessive muscular creatinine release Severe hepatic failure / cirrhosis, severe protein malnutrition / starvation, rhabdomyolysis, hemodialysis

  • 4. Creatinine Biochemistry and Analytical Quantification
  • Biosynthesis and Physiology

Synthesis: Synthesized in hepatocytes, the pancreas, and kidneys from glycine, arginine, and methionine, creatine enters circulation and is taken up by skeletal muscle.

Muscle Cycling: Muscle creatine kinase (CK) phosphorylates creatine to high-energy phosphocreatine . Through spontaneous, non-enzymatic, irreversible cyclization, approximately 1 % to 2 % 1\%\text{ to }2\% 1% to 2% of total muscle creatine/phosphocreatine converts daily to creatinine .

Constancy: Daily endogenous creatinine production is remarkably stable and directly proportional to total functional skeletal muscle mass. It is unaffected by dietary protein intake, hydration status, or protein catabolism.

Renal Excretion: Creatinine is freely filtered by the glomeruli and is neither reabsorbed nor metabolized by the renal tubules. Proximal tubules actively secrete a small fraction ( 7 % to 10 % 7\%\text{ to }10\% 7% to 10% in healthy kidneys, rising up to 20 % 20\% 20% in severe renal failure).

Reference Intervals:

Adult Males: 0.7 to 1.3 mg/dL 0.7\text{ to }1.3\text{ mg/dL} 0.7 to 1.3 mg/dL ( 62 to 115 μ mol/L 62\text{ to }115\text{ }\mu\text{mol/L} 62 to 115 μ mol/L )

Adult Females: 0.5 to 1.1 mg/dL 0.5\text{ to }1.1\text{ mg/dL} 0.5 to 1.1 mg/dL ( 44 to 97 μ mol/L 44\text{ to }97\text{ }\mu\text{mol/L} 44 to 97 μ mol/L ) (lower baseline due to lesser skeletal muscle mass)

The Jaffe Reaction (Alkaline Picrate)

Principle: Creatinine reacts with picric acid (trinitrophenol) in an alkaline medium ( NaOH \text{NaOH} NaOH ) to form an orange-red tautomeric coordinate chelate known as the Janovski complex .

Spectrophotometric Detection: Measured at 500 to 520 nm 500\text{ to }520\text{ nm} 500 to 520 nm .

Non-Creatinine Chromogen Interferences: The classic endpoint Jaffe method is notoriously non-specific; up to 20 % 20\% 20% of measured color in normal serum is caused by non-creatinine chromogens:

Positive Fast-Reacting Interferents: Acetoacetate, acetone (react within seconds).

Positive Slow-Reacting Interferents: Glucose, plasma proteins, ascorbic acid, cephalosporin antibiotics (cefazolin, cefoxitin), pyruvate (react over minutes).

Negative Interference: Bilirubin causes severe false-negative bias by undergoing alkaline oxidation to biliverdin, which degrades the Janovski complex.

The Kinetic Jaffe Assay: Developed to overcome chromogen cross-reactivity by measuring the differential rate of absorbance increase between 20 and 80 seconds 20\text{ and }80\text{ seconds} 20 and 80 seconds following reagent addition. Fast-reacting acetoacetate reacts before 20 seconds, whereas slow-reacting glucose and cephalosporins react primarily after 80 to 100 seconds.

Enzymatic Creatinine Methods (Creatininase / Creatinase Cascade): Creatinine + H 2 O → Creatininase Creatine \text{Creatinine} + \text{H}_2\text{O} \xrightarrow{\text{Creatininase}} \text{Creatine} Creatinine + H 2 ​ O Creatininase ​ Creatine Creatine + H 2 O → Creatinase Sarcosine + Urea \text{Creatine} + \text{H}_2\text{O} \xrightarrow{\text{Creatinase}} \text{Sarcosine} + \text{Urea} Creatine + H 2 ​ O Creatinase ​ Sarcosine + Urea Sarcosine + O 2 + H 2 O → Sarcosine Oxidase Glycine + Formaldehyde + H 2 O 2 \text{Sarcosine} + \text{O}_2 + \text{H}_2\text{O} \xrightarrow{\text{Sarcosine Oxidase}} \text{Glycine} + \text{Formaldehyde} + \text{H}_2\text{O}_2 Sarcosine + O 2 ​ + H 2 ​ O Sarcosine Oxidase ​ Glycine + Formaldehyde + H 2 ​ O 2 ​ H 2 O 2 + Chromogen → Peroxidase Colored Dye (Pink-Red) \text{H}_2\text{O}_2 + \text{Chromogen} \xrightarrow{\text{Peroxidase}} \text{Colored Dye (Pink-Red)} H 2 ​ O 2 ​ + Chromogen Peroxidase ​ Colored Dye (Pink-Red) Enzymatic assays completely eliminate cephalosporin, acetone, and ketoacid interferences, providing superior analytical specificity.

5. Assessment of Glomerular Filtration Rate (GFR)

Glomerular Filtration Rate (GFR) represents the total volume of fluid filtered through the functional glomerular capillaries into Bowman's capsule per unit time (normal ≈ 120 − 130 mL/min / 1.73 m 2 \approx 120 - 130\text{ mL/min}/1.73\text{ m}^2 ≈ 120 − 130 mL/min /1.73 m 2 ).

Creatinine Clearance ( C c r C_{cr} C cr ​ )

Creatinine clearance utilizes a timed 24-hour urine collection paired with a mid-point venous blood draw to estimate GFR:

C c r = U × V P × 1.73 A C_{cr} = \frac{U \times V}{P} \times \frac{1.73}{A} C cr ​ = P U × V ​ × A 1.73 ​

U = Urine creatinine concentration in mg/dL U = \text{Urine creatinine concentration in mg/dL} U = Urine creatinine concentration in mg/dL

P = Plasma or serum creatinine concentration in mg/dL P = \text{Plasma or serum creatinine concentration in mg/dL} P = Plasma or serum creatinine concentration in mg/dL

V = Urine flow rate in mL/min = Total 24-hour urine volume in mL Collection duration in minutes (24 hours × 60 = 1440 minutes) V = \text{Urine flow rate in mL/min} = \frac{\text{Total 24-hour urine volume in mL}}{\text{Collection duration in minutes (24 hours} \times 60 = 1440\text{ minutes)}} V = Urine flow rate in mL/min = Collection duration in minutes (24 hours × 60 = 1440 minutes) Total 24-hour urine volume in mL ​

1.73 / A = Body Surface Area (BSA) normalization factor 1.73 / A = \text{Body Surface Area (BSA) normalization factor} 1.73/ A = Body Surface Area (BSA) normalization factor , where 1.73 m 2 1.73\text{ m}^2 1.73 m 2 represents standard human body surface area, and A A A is the patient's individual BSA calculated from height and weight using the DuBois formula: A (m 2 ) = Weight (kg) 0.425 × Height (cm) 0.725 × 0.007184 A\text{ (m}^2) = \text{Weight (kg)}^{0.425} \times \text{Height (cm)}^{0.725} \times 0.007184 A (m 2 ) = Weight (kg) 0.425 × Height (cm) 0.725 × 0.007184

Reference Intervals:

  • Adult Males: 97 to 137 mL/min 97\text{ to }137\text{ mL/min} 97 to 137 mL/min
  • Adult Females: 88 to 128 mL/min 88\text{ to }128\text{ mL/min} 88 to 128 mL/min

Sources of Error: Incomplete 24-hour urine collection is the most frequent pre-analytical error. Technologists assess collection completeness by verifying total 24-hour creatinine excretion (expected: 15 − 25 mg/kg/day 15-25\text{ mg/kg/day} 15 − 25 mg/kg/day in men, 10 − 20 mg/kg/day 10-20\text{ mg/kg/day} 10 − 20 mg/kg/day in women). In moderate-to-severe renal failure, C c r C_{cr} C cr ​ overestimates true GFR due to increased proximal tubular creatinine secretion.

Serum Cystatin C (Alternative GFR Biomarker)

Biochemistry: A 13 kDa 13\text{ kDa} 13 kDa non-glycosylated basic protein belonging to the cysteine protease inhibitor superfamily.

Physiological Advantages: Produced by all nucleated cells at a constant, unvarying transcription rate. Freely filtered at the glomerulus, completely reabsorbed by proximal tubular epithelial cells, and catabolized. It does not return to circulation and is not secreted by tubules.

Diagnostic Superiority: Serum Cystatin C concentration is largely independent of muscle mass and dietary protein intake , although thyroid dysfunction, high-dose corticosteroids, and inflammation can shift it. It serves as a sensitive biomarker for detecting early, mild GFR reductions ( 60 − 90 mL/min / 1.73 m 2 60-90\text{ mL/min}/1.73\text{ m}^2 60 − 90 mL/min /1.73 m 2 , the "creatinine-blind zone") and is the marker of choice in elderly, pediatric, amputee, cirrhotic, or cachectic populations.

  • 6. Uric Acid Biochemistry and Pathologies
  • Purine Catabolism

Uric acid is the terminal oxidation product of purine nucleoside catabolism (adenine and guanine derived from nucleic acid breakdown) in humans.

Adenosine / Guanosine → Inosine / Xanthine → Xanthine Oxidase Uric Acid \text{Adenosine / Guanosine} \rightarrow \text{Inosine / Xanthine} \xrightarrow{\text{Xanthine Oxidase}} \text{Uric Acid} Adenosine / Guanosine → Inosine / Xanthine Xanthine Oxidase ​ Uric Acid

In other mammals, hepatic uricase (urate oxidase) converts uric acid into soluble allantoin. Humans experienced an evolutionary mutational silencing of the uricase gene, rendering humans uniquely susceptible to hyperuricemia and urate precipitation.

Physiological Properties: Weak acid ( pKa 1 = 5.57 \text{pKa}_1 = 5.57 pKa 1 ​ = 5.57 ). At physiological blood pH of 7.40 7.40 7.40 , > 98 % >98\% > 98% exists as soluble monosodium urate . In acidic urine ( pH < 5.5 \text{pH } < 5.5 pH < 5.5 ), insoluble free uric acid predominates, precipitating as rhombic or rosette crystals and forming radiolucent uric acid calculi.

Normal Reference Intervals:

Adult Males: 3.5 to 7.2 mg/dL 3.5\text{ to }7.2\text{ mg/dL} 3.5 to 7.2 mg/dL ( 208 to 428 μ mol/L 208\text{ to }428\text{ }\mu\text{mol/L} 208 to 428 μ mol/L )

Adult Females: 2.6 to 6.0 mg/dL 2.6\text{ to }6.0\text{ mg/dL} 2.6 to 6.0 mg/dL ( 155 to 357 μ mol/L 155\text{ to }357\text{ }\mu\text{mol/L} 155 to 357 μ mol/L )

Analytical Methods for Uric Acid

Enzymatic Uricase Differential Method (Reference Standard): Uric Acid + 2 H 2 O + O 2 → Uricase Allantoin + CO 2 + H 2 O 2 \text{Uric Acid} + 2\text{H}_2\text{O} + \text{O}_2 \xrightarrow{\text{Uricase}} \text{Allantoin} + \text{CO}_2 + \text{H}_2\text{O}_2 Uric Acid + 2 H 2 ​ O + O 2 ​ Uricase ​ Allantoin + CO 2 ​ + H 2 ​ O 2 ​

Uric acid exhibits strong, specific ultraviolet light absorption at 293 nm 293\text{ nm} 293 nm , whereas the reaction product allantoin does not absorb at this wavelength. The stoichiometric decrease in absorbance at 293 nm 293\text{ nm} 293 nm following uricase incubation is directly proportional to uric acid concentration.

Coupled Uricase-Peroxidase (Trinder) Assay: The generated H 2 O 2 \text{H}_2\text{O}_2 H 2 ​ O 2 ​ is coupled to 4-AAP and a chromogen by peroxidase to yield a colored quinoneimine dye ( 500 − 540 nm 500-540\text{ nm} 500 − 540 nm ).

Caraway Method (Phosphotungstic Acid): Chemical oxidation of uric acid reduces phosphotungstic acid in alkaline carbonate to tungsten blue ( 650 − 700 nm 650-700\text{ nm} 650 − 700 nm ); prone to reducing interferents (ascorbate, acetaminophen).

Clinical Pathologies of Uric Acid

Hyperuricemia ( > 7.0 mg/dL > 7.0\text{ mg/dL} > 7.0 mg/dL in men, > 6.0 mg/dL > 6.0\text{ mg/dL} > 6.0 mg/dL in women):

Primary Gout: Supersaturation leads to monosodium urate monohydrate crystal precipitation within avascular articular cartilage and synovial joints (classically the first metatarsophalangeal joint, termed podagra ). Under polarized light microscopy with a full-wave red compensator, intracellular urate crystals appear as needle-shaped crystals with strong negative birefringence (yellow when oriented parallel to the compensator slow axis; blue when perpendicular).

Lesch-Nyhan Syndrome: Rare X-linked recessive inborn error characterized by complete deficiency of Hypoxanthine-Guanine Phosphoribosyltransferase (HGPRT) . Loss of purine salvage leads to massive purine overproduction, extreme hyperuricemia, orange "uric acid sand" in infant diapers, choreoathetosis, spasticity, and compulsive self-mutilation .

Tumor Lysis Syndrome (TLS): Oncologic emergency occurring during cytotoxic chemotherapy for high-grade hematologic malignancies (Burkitt lymphoma, acute lymphoblastic leukemia). Massive rapid lysis of neoplastic cells releases enormous intracellular purine loads, overwhelming renal clearance and causing acute obstructive uric acid nephropathy and oliguric renal failure. Prevented via aggressive hydration and therapy with allopurinol (xanthine oxidase inhibitor) or rasburicase (recombinant uricase).

Secondary Hyperuricemia: Chronic renal failure (impaired urate clearance), diabetic ketoacidosis or starvation (acetoacetate and β \beta β -hydroxybutyrate competitively inhibit tubular urate secretion), and chronic lead nephropathy ("saturnine gout").

Hypouricemia ( < 2.0 mg/dL < 2.0\text{ mg/dL} < 2.0 mg/dL ): Observed in Fanconi syndrome (defective proximal tubular reabsorption), severe end-stage hepatocellular disease (impaired purine synthesis), or over-treatment with allopurinol or uricosuric agents (probenecid).